DermTech Past Earnings Performance
Past criteria checks 0/6
DermTech's earnings have been declining at an average annual rate of -36.7%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 33% per year.
Key information
-36.7%
Earnings growth rate
-5.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 33.0% |
| Return on equity | -224.1% |
| Net Margin | -572.2% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 44%
May 21
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%
Mar 02Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price
Dec 28Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023
May 10DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%
May 06We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02Revenue & Expenses Breakdown
How DermTech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 16 | -90 | 74 | 14 |
| 31 Dec 23 | 15 | -101 | 83 | 15 |
| 30 Sep 23 | 14 | -110 | 90 | 17 |
| 30 Jun 23 | 14 | -120 | 97 | 19 |
| 31 Mar 23 | 14 | -118 | 98 | 22 |
| 31 Dec 22 | 15 | -117 | 95 | 24 |
| 30 Sep 22 | 15 | -115 | 92 | 25 |
| 30 Jun 22 | 14 | -106 | 84 | 24 |
| 31 Mar 22 | 13 | -93 | 75 | 20 |
| 31 Dec 21 | 12 | -78 | 62 | 16 |
| 30 Sep 21 | 11 | -63 | 50 | 12 |
| 30 Jun 21 | 9 | -52 | 41 | 9 |
| 31 Mar 21 | 7 | -45 | 35 | 7 |
| 31 Dec 20 | 6 | -36 | 30 | 5 |
| 30 Sep 20 | 5 | -31 | 27 | 4 |
| 30 Jun 20 | 5 | -27 | 24 | 3 |
| 31 Mar 20 | 4 | -21 | 19 | 3 |
| 31 Dec 19 | 3 | -20 | 15 | 2 |
| 30 Sep 19 | 2 | -18 | 12 | 2 |
| 30 Jun 19 | 2 | -14 | 8 | 2 |
| 31 Mar 19 | 3 | -13 | 7 | 2 |
| 31 Dec 18 | 2 | -10 | 6 | 2 |
| 31 Dec 17 | 2 | -8 | 6 | 2 |
| 30 Jun 14 | 0 | -6 | 2 | 3 |
| 31 Mar 14 | 0 | -6 | 2 | 2 |
Quality Earnings: DMTK.Q is currently unprofitable.
Growing Profit Margin: DMTK.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DMTK.Q is unprofitable, and losses have increased over the past 5 years at a rate of 36.7% per year.
Accelerating Growth: Unable to compare DMTK.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DMTK.Q is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: DMTK.Q has a negative Return on Equity (-224.1%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 02:13 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DermTech, Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sally Yanchus | Brookline Capital Markets |
| Mark Massaro | BTIG |
| Alexander Nowak | Craig-Hallum Capital Group LLC |